These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 1395925)

  • 21. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
    Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
    Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.
    Mandelli F; Petti MC; Ardia A; Di Pietro N; Di Raimondo F; Ganzina F; Falconi E; Geraci E; Ladogana S; Latagliata R
    Eur J Cancer; 1991; 27(6):750-5. PubMed ID: 1829918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Seven day cytosine arabinoside administered subcutaneously plus daunorubicin for remission induction in AML.
    Holowiecki J; Rudzka E; Jarczok K; Holowiecka B; Krawczyk M; Duraj M; Japa J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(6):792-7. PubMed ID: 6200390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Consolidation therapy with high-dose cytarabine and daunorubicin for prolonged disease free survival in acute myelocytic leukemia].
    Qiau Z; Wang C; Yang L
    Zhonghua Nei Ke Za Zhi; 1996 Aug; 35(8):545-8. PubMed ID: 9594148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [DCTP(II) combination chemotherapy of adult acute nonlymphocytic leukemia].
    Kobayashi T; Ogawa M; Kuraishi Y; Nagata T; Aiba K; Nakamura T; Usui N; Yamazaki H; Ichiba K; Isogai Y
    Nihon Ketsueki Gakkai Zasshi; 1988 Aug; 51(5):855-63. PubMed ID: 3206983
    [No Abstract]   [Full Text] [Related]  

  • 28. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
    J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of acute non lymphoid leukemia (ANLL) in elderly patients. The GIMEMA experience.
    Resegotti L
    Leukemia; 1992; 6 Suppl 2():72-5. PubMed ID: 1578948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vincristine (NSC-67574), cytosine arabinoside (NSC-63878), 6 thioguanine (NSC-752) and daunorubicin (NSC-82151) (VAT-D): a pilot study of combination chemotherapy for remission induction in acute myeloid leukemia in adults.
    Sartiano GP; Pfrimmer WJ; Turner AR
    Med Pediatr Oncol; 1978; 4(3):205-12. PubMed ID: 277748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.
    Büchner T; Urbanitz D; Hiddemann W; Rühl H; Ludwig WD; Fischer J; Aul HC; Vaupel HA; Kuse R; Zeile G
    J Clin Oncol; 1985 Dec; 3(12):1583-9. PubMed ID: 3906048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.
    Stone RM; Mazzola E; Neuberg D; Allen SL; Pigneux A; Stuart RK; Wetzler M; Rizzieri D; Erba HP; Damon L; Jang JH; Tallman MS; Warzocha K; Masszi T; Sekeres MA; Egyed M; Horst HA; Selleslag D; Solomon SR; Venugopal P; Lundberg AS; Powell B
    J Clin Oncol; 2015 Apr; 33(11):1252-7. PubMed ID: 25732165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
    Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
    Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of aggressive chemotherapy for acute nonlymphoblastic leukemia in adults.
    Armitage JO; Burns CP; Dick FR; Aunan SB; Slymen DJ
    Cancer Treat Rep; 1982 Nov; 66(11):1917-24. PubMed ID: 7139637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside.
    Cassileth PA; Katz ME
    Cancer Treat Rep; 1977 Nov; 61(8):1441-5. PubMed ID: 922749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
    Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
    Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia].
    Bian SG; Hao YS; Wang ZC
    Zhonghua Nei Ke Za Zhi; 1990 Jan; 29(1):22-5, 60. PubMed ID: 2401166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
    Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
    Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.